Study to determine rate of novel coronavirus infection in U.S. children

May 15, 2020
Posted in

Researchers at Vanderbilt University Medical Center are leading a nationwide study to determine the rate of novel coronavirus infection in U.S. children and their families. The study, named the HEROS (Human Epidemiology and Response to SARS-CoV-2) study and funded by the National Institute of Allergy and Infectious Diseases (NIAID), aims to gain insight into how many children ages 1 to 21 have been infected, the percentage of those infected who develop symptoms of COVID-19 and any differences in immune responses to the virus between children and adults within the same household.

Study aims to shield health workers from COVID-19 infection

VUMC Reporter
April 2, 2020

Vanderbilt University Medical Center is playing a key role in a national effort to establish a registry of U.S. health care workers and test whether the anti-malarial drug hydroxychloroquine (HCQ) will protect them, their patients and their families from COVID-19. The Board of Governors of the non-profit Patient-Centered Outcomes Research Institute (PCORI) in Washington, D.C., today approved up to $50 million to fund the initiative, known as the Healthcare Worker Exposure Response and Outcomes (HERO) research program, to be led by the Duke Clinical Research Institute (DRCI). Co-chairs of the HERO Steering Committee are Russell Rothman, MD, MPP, VUMC Senior Vice President for Population and Public Health, and Judith Currier, MD, professor of Medicine and chief of the Division of Infectious Diseases at UCLA Medical Center, Santa Monica. Fellow steering committee member Sean Collins, MD, MSCI, professor and executive vice chair of the Department of Emergency Medicine at VUMC, will lead VUMC’s engagement in the HERO study and will serve as the site’s principal investigator. He also is a member of the protocol advisory committee.